• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Gains Over 100 Points; AerSale Shares Plunge After Q4 Results

    3/8/24 2:51:42 PM ET
    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Consumer Discretionary
    Get the next $AMLX alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday.

    The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500 also fell, dropping, 0.20% to 5,146.8.

    Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 5% Dividend Yields

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 0.9% on Friday.

    In trading on Friday, information technology shares fell by 1.8%.

     

    Top Headline

     

    Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000. The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.

    Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.

     

    Equities Trading UP

     

    Willdan Group, Inc. (NASDAQ:WLDN) shares shot up 25% to $24.85 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.

    Shares of The Joint Corp. (NASDAQ:JYNT) got a boost, surging 31% to $11.94 following fourth-quarter results.

    Safe and Green Development Corporation (NASDAQ:SGD) shares were also up, gaining 134% to $1.54 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.

     

    Equities Trading DOWN

     

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) shares dropped 82% to $3.3650 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.

    Shares of AerSale Corporation (NASDAQ:ASLE) were down 27% to $6.82 after the company reported worse-than-expected fourth-quarter financial results.

    BigBear.ai Holdings, Inc. (NYSE:BBAI) was down, falling 32% to $2.5750 after the company reported worse-than-expected fourth-quarter financial results.

    Also Check This Out: Cisco, Robinhood And 2 Other Stocks Insiders Are Selling

     

    Commodities

     

    In commodity news, oil traded down 1.5% to $77.73 while gold traded up 1% at $2,186.90.

    Silver traded down 0.2% to $24.54 on Friday while copper fell 1.1% to $3.8840.

     

    Euro zone

     

    European shares were mixed today. The eurozone’s STOXX 600 gained 0.02%, London’s FTSE 100 fell 0.43% while Spain’s IBEX 35 Index rose 0.13% The German DAX fell 0.16% French CAC 40 rose 0.15% while Italy’s FTSE MIB Index fell 0.04%.

    The eurozone economy stagnated during the fourth quarter compared to a 0.1% decline in the prior three-month period. French trade deficit increased to €7.4 billion in January from €6.4 billion in the prior month. Spanish industrial output declined by 0.6% year-over-year in January. Producer prices in Germany declined by 4.4% year-over-year in January, while industrial output increased by 1.0% month-over-month for January.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Friday, with Japan’s Nikkei 225 gaining 0.23%, Hong Kong’s Hang Seng Index gaining 0.76% and China’s Shanghai Composite Index gaining 0.61%.

    The gauge for Japan’s service sector climbed to 51.3 in February versus prior month’s reading of 50.2. The index of leading economic indicators in Japan fell to 109.9 in January versus a revised reading of 110.5 in December, while index of coincident economic indicators fell to 110.2 in January versus a revised 116.0 in the previous month. Household spending in Japan dipped by 6.3% year-over-year in January.

     

    Economics

     

    Nonfarm payrolls beat economist estimates, coming at 275,000 in February compared to the expected 200,000.

    The unemployment rate rose from 3.7% to 3.9%, surprising estimates of 3.7%.

    Average hourly wages grew at a 0.1% monthly pace in February, easing from the downwardly revised 0.5% growth in January, and below the expected 0.3%.

    The total number of active U.S. oil rigs fell by 1 rig this week, Baker Hughes Inc reported.

    Now Read This: Top 3 Industrials That Are Preparing To Pump In Q1

    Get the next $AMLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMLX
    $ASLE
    $BBAI
    $JYNT

    CompanyDatePrice TargetRatingAnalyst
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    BigBear.ai Inc.
    $BBAI
    1/7/2026$6.00Overweight → Neutral
    Cantor Fitzgerald
    AerSale Corporation
    $ASLE
    7/11/2025$6.00Buy → Hold
    Truist
    Amylyx Pharmaceuticals Inc.
    $AMLX
    7/10/2025$10.00Buy
    Goldman
    Amylyx Pharmaceuticals Inc.
    $AMLX
    6/24/2025$17.00Buy
    Guggenheim
    Amylyx Pharmaceuticals Inc.
    $AMLX
    6/17/2025$12.00Buy
    Citigroup
    Amylyx Pharmaceuticals Inc.
    $AMLX
    5/30/2025Buy
    TD Cowen
    Amylyx Pharmaceuticals Inc.
    $AMLX
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Amylyx Pharmaceuticals with a new price target

    Stifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    3/3/26 8:26:33 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigBear.ai downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded BigBear.ai from Overweight to Neutral and set a new price target of $6.00

    1/7/26 8:53:55 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    AerSale downgraded by Truist with a new price target

    Truist downgraded AerSale from Buy to Hold and set a new price target of $6.00

    7/11/25 8:09:46 AM ET
    $ASLE
    Industrial Specialties
    Consumer Discretionary

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    SEC Filings

    View All

    SEC Form S-8 filed by Amylyx Pharmaceuticals Inc.

    S-8 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    3/3/26 4:03:34 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Amylyx Pharmaceuticals Inc.

    S-3ASR - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    3/3/26 8:01:18 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Amylyx Pharmaceuticals Inc.

    10-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    3/3/26 7:10:58 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jobson Charles E bought $130,874 worth of Common (15,397 units at $8.50), increasing direct ownership by 0.94% to 1,645,294 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/17/26 5:36:26 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $3,898 worth of Common (448 units at $8.70), increasing direct ownership by 0.03% to 1,639,597 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/13/26 5:16:01 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $174,780 worth of Common (17,478 units at $10.00), increasing direct ownership by 1% to 1,639,149 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    1/27/26 8:45:38 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigBear.ai Announces Fourth Quarter 2025 Results; Releases 2026 Financial Outlook

    Closed 2025 with strongest financial position in Company history Total cash and investments of $462 million as of December 31, 2025 Settled the remaining $125 million of 2029 Convertible notes, primarily through the Company's exercise of debt-to-equity conversion features in January 2026. Closed acquisitions of Ask Sage (December 2025), and CargoSeer (January 2026), and expanded into the Middle East, which positions the Company for solid growth in 2026 The Company projects full-year 2026 revenue between $135 million and $165 million, representing approximately 17% growth at the midpoint compared to full-year 2025 revenue of $128 million BigBear.ai Holdings, Inc. (NYSE:BBAI)

    3/2/26 4:15:00 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Willdan Selected by Mt. SAC for $49 Million Distributed Energy and Resiliency Project

    Willdan Group, Inc. (NASDAQ:WLDN) announced today that it was selected by Mt. San Antonio College (Mt. SAC) in California to implement a $49 million energy services contract. The scope of work consists of the turnkey delivery of distributed energy resources (DERs) and infrastructure upgrades, including solar PV systems, a battery energy storage system, EV charging stations, and a comprehensive parking lot redesign. Construction is expected to be completed by the third quarter of 2027. Willdan is listed as a qualified energy service company in the state of California and holds a Master Services Agreement with the Foundation for California Community Colleges to implement DERs at California

    2/27/26 9:15:00 AM ET
    $WLDN
    Military/Government/Technical
    Consumer Discretionary

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Mazzariello Gina sold $48,352 worth of shares (3,419 units at $14.14), decreasing direct ownership by 2% to 141,274 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    2/25/26 4:00:03 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Jobson Charles E bought $130,874 worth of Common (15,397 units at $8.50), increasing direct ownership by 0.94% to 1,645,294 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/17/26 5:36:26 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    Large owner Jobson Charles E bought $3,898 worth of Common (448 units at $8.70), increasing direct ownership by 0.03% to 1,639,597 units (SEC Form 4)

    4 - JOINT Corp (0001612630) (Issuer)

    2/13/26 5:16:01 PM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Willdan Group Reports Fourth Quarter and Full Year 2025 Results and Provides 2026 Outlook

    Willdan Group, Inc. ("Willdan") (NASDAQ:WLDN) today announced its financial results for the fourth quarter and fiscal year ended January 2, 2026 and outlook for 2026. Fourth Quarter 2025 Highlightsa Contract revenue of $173.7 million, up 20.6%. Net revenueb of $89.5 million, up 12.9%. Net income of $18.7 million, up 143.4%. Adjusted EBITDAb of $20.0 million, up 13.2%. GAAP Diluted EPS of $1.23, up 132.1%. Adjusted Diluted EPSb of $1.57, up 109.3%. Fiscal Year 2025 Highlightsa Contract revenue of $681.6 million, up 20.5%. Net revenueb of $364.8 million, up 23.1%. Net income of $52.6 million, up 132.9%. Adjusted EBITDAb of $79.5 million, up 40.2%. GAAP Di

    2/26/26 4:08:00 PM ET
    $WLDN
    Military/Government/Technical
    Consumer Discretionary

    The Joint Corp. to Report 2025 Fourth Quarter and Full Year Results on Thursday, March 12 and Host Conference Call and Webcast

    SCOTTSDALE, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its 2025 fourth quarter and full year financial results on Thursday, March 12, 2026, after the market close and host a conference call and simultaneous webcast at 5:00 p.m. ET that day. During the call, The Joint Corp. President and CEO Sanjiv Razdan and CFO Scott Bowman will review the Company's financial results and provide a business update, followed by a question-and-answer session. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing

    2/26/26 7:05:00 AM ET
    $JYNT
    Multi-Sector Companies
    Miscellaneous

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $AMLX
    $ASLE
    $BBAI
    $JYNT
    Leadership Updates

    Live Leadership Updates

    View All

    Mission Critical Group Appoints Julie Peffer as Chief Financial Officer

    MCKINNEY, Texas, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mission Critical Group ("MCG"), a critical power infrastructure company specializing in the design, manufacturing, delivery, and service of advanced electrical systems, today announces the appointment of Julie Peffer as Chief Financial Officer. Peffer brings more than three decades of experience leading financial operations and strategic growth initiatives across global organizations, including Amazon Web Services (AWS), Flowserve, Raytheon, Lennox International, and Textron. She joins MCG from BigBear.ai (NYSE:BBAI), where she served as CFO and guided the company's financial strategy through rapid expansion in the defense and artificial

    10/21/25 8:05:00 AM ET
    $BBAI
    $NINE
    Computer Software: Prepackaged Software
    Technology
    Oilfield Services/Equipment
    Energy

    AerSale® Appoints Paul Hechenberger as Senior Vice President, General Counsel & Corporate Secretary

    AerSale® (NASDAQ:ASLE), a leading provider of aviation products and services, today announced the appointment of Paul Hechenberger as Senior Vice President, General Counsel & Corporate Secretary. Hechenberger brings more than four decades of legal, leadership, and aerospace experience to AerSale, with extensive expertise in complex commercial transactions, mergers and acquisitions, corporate governance, and compliance. Prior to joining AerSale, Hechenberger was a Partner with Miami-based law firm Shutts & Bowen. His previous leadership roles include serving as General Counsel at iAero Group, Deputy General Counsel at Spirit AeroSystems, General Counsel at BBA Aviation (Aftermarket Servi

    8/19/25 4:05:00 PM ET
    $ASLE
    Industrial Specialties
    Consumer Discretionary

    Safe and Green Development Appoints New Board Members Following Acquisition of Resource Group US Holdings LLC

    MIAMI, FL, June 20, 2025 (GLOBE NEWSWIRE) -- Safe and Green Development Corporation (NASDAQ:SGD) ("SGD" or the "Company") is pleased to announce the appointment of three new members to its Board of Directors, effective immediately. These appointments follow the successful completion of the Company's acquisition of Resource Group US Holdings LLC and represent a strategic step in furthering SGD's commitment to operational growth, innovation, and development. The newly elected directors; Bjarne Borg, James D. Burnham, and Anthony M. Cialone, bring decades of combined experience across real estate development, environmental engineering, private equity, and renewable technologies. Each of them

    6/20/25 8:30:00 AM ET
    $SGD
    Real Estate
    Finance